Abstract Number: 2425 • 2014 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Stable Follow up Visits – 3 Month Versus 6 Month Intervals
Background/Purpose Specialist visits are a contributing factor to the rising cost of healthcare and payment models increasingly encourage decreased outpatient specialty visits. Due to monitoring…Abstract Number: 2404 • 2014 ACR/ARHP Annual Meeting
RA Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-Term Response When Switched to SC MTX Monotherapy
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy, but many patients do not achieve adequate response to oral therapy for reasons of…Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting
Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database
Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort
Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…Abstract Number: 2032 • 2014 ACR/ARHP Annual Meeting
Psychological Factors Predict Adherence to Methotrexate (MTX) in Rheumatoid Arthritis (RA); Findings from a Systematic Review of Rates, Predictors and Associations with Patient Outcomes
Background/Purpose: Methotrexate (MTX) is a first line therapy for Rheumatoid Arthritis (RA). Treatment response to MTX is not universal, and nonadherence may partially explain poor…Abstract Number: 2031 • 2014 ACR/ARHP Annual Meeting
Early Adherence to Methotrexate in Rheumatoid Arthritis (RA) Is High: a Prospective Longitudinal Study of New Users
Background/Purpose Methotrexate (MTX) is the recommended first-line DMARD for rheumatoid arthritis (RA) in most countries, however response is not universal. Non-adherence may explain this to…Abstract Number: 1839 • 2014 ACR/ARHP Annual Meeting
Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis
Background/Purpose: Methotrexate (MTX) and anti-TNF drugs have been hypothesized to increase the risk of a first non-melanoma skin cancer (NMSC). Among patients with prior NMSC,…Abstract Number: 1488 • 2014 ACR/ARHP Annual Meeting
Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~
Background/Purpose Iguratimod (IGU) is a small-molecule antirheumatic drug that was approved in Japan in September 2012. IGU suppressed tumor necrosis factor-alpha-induced production of interleukin (IL)-6,…Abstract Number: 1448 • 2014 ACR/ARHP Annual Meeting
A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis
Background/Purpose Methotrexate is the reference treatment for rheumatoid arthritis (RA). It has potentially serious side effects which can be prevented by an improvement in patient’s…Abstract Number: 1131 • 2014 ACR/ARHP Annual Meeting
Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis
Background/Purpose: For patients with rheumatoid arthritis (RA) who fail to attain remission or low disease activity after 6 months of methotrexate (MTX) treatment, TNF inhibitors…Abstract Number: 2365 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Did Not Affect Discontinuation Rate Of Etanercept Due To Ineffectiveness: Six-Year Results From Japanese Multicenter Registry System
Background/Purpose: In the last decade, treatment with tumor necrosis factor (TNF) inhibitors has significantly improved the outcome in patients with rheumatoid arthritis (RA). Recent studies…Abstract Number: 437 • 2013 ACR/ARHP Annual Meeting
Patterns Of Use Of Oral and Subcutaneous Methotrexate Use In Rheumatoid Arthritis Patients Enrolled In The U.S. Medicare Program
Background/Purpose: Although methotrexate (MTX) is the cornerstone of RA treatment, use of oral and subcutaneous (SC) preparations in real-world settings is not well characterized. Methods:…Abstract Number: 2339 • 2013 ACR/ARHP Annual Meeting
Patient Evaluations Of Subcutaneous Golimumab Delivery By Autoinjector (SmartJect®) For Treatment Of Rheumatoid Arthritis
Background/Purpose: Self-injection of subcutaneous (SC) golimumab (GLM) using an autoinjector device may be useful for patients with rheumatoid arthritis (RA), especially if they have functional…Abstract Number: L3 • 2013 ACR/ARHP Annual Meeting
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
Background/Purpose: VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). The objective of this 24-week, randomized, placebo-controlled, double-blind,…Abstract Number: 2318 • 2013 ACR/ARHP Annual Meeting
Disease Activity in Moderate and Severe Rheumatoid Arthritis At Discontinuation in 10-Year Open-Label Extension Studies With Etanercept
Background/Purpose: Retention rates may be used as a surrogate of long-term effectiveness of drug therapy in open-label studies. Studies have reported that patients (pts)…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- Next Page »